GH
HealthcareGuardant Health, Inc. · Medical - Diagnostics & Research · $16B
What is Guardant Health, Inc.?
Guardant Health is a precision oncology company built around liquid biopsy technology — blood-based tests that detect cancer signals without invasive tissue sampling. Headquartered in Redwood City, California, the company serves both clinical and biopharmaceutical customers across the United States and internationally.
Guardant Health generates revenue by providing liquid biopsy tests that analyze circulating tumor DNA from a patient's blood sample. These tests help oncologists identify genetic alterations driving a patient's cancer, guide treatment selection, and monitor disease progression. The company also sells data analytics services and research platforms to biopharmaceutical companies, and offers companion diagnostic development services that support drug approval processes.
Guardant Health was incorporated in 2011 and is headquartered in Redwood City, California.
- Guardant360 and Guardant360 CDx — advanced-stage cancer liquid biopsy tests
- GuardantOMNI — comprehensive genomic profiling for late-stage cancer
- GuardantINFORM — in-silico clinical-genomic research platform
- Guardant Reveal — early-stage cancer treatment selection test
- LUNAR-2 — colorectal cancer early detection test in development
Is GH a Good Stock to Buy?
UQS Score rates GH as Below Average overall, reflecting meaningful trade-offs across its five quality pillars.
Guardant Health's most notable strengths lie in its Growth and Risk profiles, both rated Strong. The company is expanding its addressable market through early detection products and biopharmaceutical partnerships, while its balance sheet and financial risk characteristics compare favorably within the healthcare sector.
The Quality pillar is rated Weak, pointing to profitability challenges common in high-investment biotech platforms. Valuation is rated Elevated, suggesting the market has already priced in a significant portion of the growth opportunity.
Pro members can view the complete pillar breakdown and underlying financial metrics to see exactly where GH stands relative to sector peers. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GH pay dividends?
No — Guardant Health, Inc. does not currently pay a dividend.
Guardant Health does not pay a dividend. As a growth-stage precision oncology company, capital is directed toward expanding its test menu, funding clinical studies for products like LUNAR-2, and building out its biopharmaceutical services business. Income-focused investors should factor this into their portfolio planning.
When does GH report earnings?
Guardant Health reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue growth has been driven by increasing clinical test volumes and expanding biopharmaceutical partnerships. The company continues to invest heavily in research and commercial infrastructure, which weighs on near-term profitability but supports its long-term product pipeline.
For the most recent quarter's results and guidance, visit Guardant Health's investor relations page directly.
GH Price History
-27.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Guardant Health, Inc.?
Based on Guardant Health, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GH Long-term Outlook
Guardant Health's Strong Growth pillar reflects a meaningful expansion runway — particularly as LUNAR-2 and other early detection products move through regulatory and commercial stages. The Strong Risk rating suggests the company's financial structure is not a near-term concern. However, the Elevated Valuation pillar indicates that much of this growth potential is already reflected in the current price, leaving limited margin for execution shortfalls. The Weak Quality pillar is the key variable to watch as the business scales toward profitability.
Growth drivers
- Expansion of liquid biopsy adoption in early-stage cancer detection
- Growing biopharmaceutical services and companion diagnostic partnerships
- International market development for existing and pipeline tests
Key risks
- Sustained operating losses while scaling commercial and R&D infrastructure
- Elevated valuation leaves little room for missed growth milestones
- Regulatory and reimbursement uncertainty for pipeline products like LUNAR-2
GH vs Peers
Guardant Health operates in a competitive landscape that includes diversified life sciences and contract research organizations with overlapping exposure to oncology and biopharma services.
Revvity offers a broader diagnostics and life sciences tools portfolio, giving it more diversified revenue streams compared to Guardant's focused oncology testing model.
Medpace is a contract research organization specializing in clinical trial management, competing with Guardant on the biopharmaceutical services side rather than the diagnostic testing side.
ICON is a large global CRO with broad therapeutic coverage, intersecting with Guardant primarily through clinical study support and oncology trial services.
Frequently Asked Questions
What does Guardant Health do?
Guardant Health develops and sells liquid biopsy tests that detect cancer-related genetic changes from a simple blood draw. Its products help oncologists select treatments for advanced and early-stage cancer patients. The company also provides data analytics platforms and development services to biopharmaceutical companies supporting drug discovery and companion diagnostic programs.
Does GH pay dividends?
No, Guardant Health does not currently pay a dividend. The company reinvests available capital into clinical development, commercial expansion, and research infrastructure. Investors seeking income from healthcare holdings should look elsewhere, as GH is positioned as a growth-oriented precision oncology platform.
When does GH report earnings?
Guardant Health follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source. For the most accurate and up-to-date schedule, check Guardant Health's investor relations page or a financial calendar service.
Is GH a good stock to buy?
The UQS Score rates GH as Below Average overall. Its Growth and Risk pillars are Strong, but Quality is Weak and Valuation is Elevated. That combination means the company has real expansion potential but faces profitability headwinds and a price that already reflects much of the upside. The full pillar breakdown is available to Pro members.
Is GH overvalued?
The UQS Valuation pillar for GH is rated Elevated, indicating the stock trades at a premium relative to fundamental benchmarks. This is common for high-growth healthcare companies with significant pipeline optionality, but it does mean investors are paying for future execution that has not yet materialized in earnings.
How does GH compare to its competitors?
Compared to peers like Revvity, Medpace, and ICON, Guardant Health is more narrowly focused on liquid biopsy and precision oncology. That focus creates a differentiated growth profile but also concentrates risk. Broader CRO and diagnostics peers tend to carry more diversified revenue, which can provide stability that a single-platform company like Guardant does not yet offer.
What is GH's market cap bracket?
Guardant Health is classified as a large-cap company. This places it among the larger publicly traded precision oncology and diagnostics businesses, reflecting significant investor interest in its liquid biopsy platform and early detection pipeline despite the company not yet being consistently profitable.
Who founded Guardant Health?
Guardant Health was co-founded by Helmy Eltoukhy and AmirAli Talasaz. Both have backgrounds in genomics and engineering, and the company was built around the idea that blood-based cancer testing could replace or complement traditional tissue biopsies. Founding details are widely available through public sources and the company's own history.
Is GH a long-term quality investment?
As a long-term quality indicator, GH presents a mixed picture. The Strong Growth pillar suggests the business is expanding its reach in a large and underpenetrated market. However, the Weak Quality pillar reflects ongoing profitability challenges that long-term investors typically want to see improve over time. Pro members can access the full analysis to assess trajectory.
What is the main competitive advantage of Guardant Health?
Guardant Health's core advantage lies in its proprietary liquid biopsy technology and the clinical-genomic dataset it has accumulated through years of testing. This dataset, housed in the GuardantINFORM platform, creates a data network effect that is difficult for newer entrants to replicate quickly. The Moat pillar is rated Neutral, reflecting both this advantage and the competitive pressures it faces.
What sector does GH belong to?
Guardant Health operates in the Healthcare sector, specifically within precision oncology and molecular diagnostics. It sits at the intersection of clinical diagnostics and biopharmaceutical services, making it relevant to investors tracking both diagnostic innovation and oncology drug development trends.
Is GH a growth stock or value stock?
Based on its UQS pillar profile, GH leans clearly toward the growth category. The Growth pillar is rated Strong, while the Valuation pillar is Elevated — a combination typical of companies where investors are paying a premium for future revenue expansion rather than current earnings power.
Unlock Full GH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare GH against precision oncology and diagnostics peers
- ✓Track Quality and Valuation changes over time
- ✓See the complete analyst-style breakdown in one place
Pro Analysis
GH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 48.0 | 29.6 | 46.0 | 83.9 | 82.4 | 0.0 | — |
GH — Pillar Breakdown
Quality
— 29.6/100 (25%)Guardant Health, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 83.9/100 (20%)Guardant Health, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Guardant Health, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Guardant Health, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 46/100 (25%)Guardant Health, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GH.
Score Composition
Financial Data
More Stock Analysis
How is the GH UQS Score Calculated?
The UQS (Unified Quality Score) for Guardant Health, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Guardant Health, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Guardant Health, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.